Researcher
Bram Verstockt
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2015 → Today
Projects
1 - 4 of 4 results
- Role of eosinophils in gut inflammation and fibrosis in inflammatory bowel diseasesFrom5 Mar 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- “Predicting response to therapy in inflammatory bowel diseases ”From23 Sep 2019 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Predicting response to treatment in patients with inflammatory bowel diseaseFrom1 Jan 2017 → TodayFunding: Foreign private sponsor - undefined
- Predicting outcomes of inflammatory bowel diseases: creating opportunities for personalized medicineFrom1 Oct 2015 → 30 Sep 2019Funding: FWO fellowships
Publications
1 - 10 of 123 results
- Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?(2021)
Authors: Inge Jacobs, Matthias Ceulemans, Lucas Wauters, Christine Breynaert, Severine Vermeire, Bram Verstockt, Tim Vanuytsel
Number of pages: 17 - ECCO Topical Review: Refractory Inflammatory Bowel Disease(2021)
Authors: Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, et al.
Pages: 1605 - 1620Number of pages: 16 - Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease(2021)
Authors: Sare Verstockt, Bram Verstockt, Kathleen Machiels, Maaike Vancamelbeke, Marc Ferrante, Isabelle Cleynen, Gert De Hertogh, Séverine Vermeire
Pages: 1564 - 1575Number of pages: 12 - Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis(2021)
Authors: Bryan Linggi, Vipul Jairath, Guangyong Zou, Lisa M Shackelton, Dermot PB McGovern, Azucena Salas, Bram Verstockt, Mark S Silverberg, Shadi Nayeri, Brian G Feagan, et al.
Number of pages: 12 - Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy(2021)
Authors: Bram Verstockt, Nurulamin M Noor, Urko M Marigorta, Polychronis Pavlidis, Parakkal Deepak, Ryan C Ungaro
Pages: 1431 - 1442Number of pages: 12 - Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients(2021)
Authors: C Jorissen, Bram Verstockt, N Schils, João Pedro Guedelha Sabino, Marc Ferrante, Séverine Vermeire
Pages: 1323 - 1327Number of pages: 5 - Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohn's Disease, Dream or Reality?(2021)
Authors: Bram Verstockt, Nélia Abreu, Joana Torres
Pages: 353 - 355 - Breaking the therapeutic ceiling in drug development in ulcerative colitis(2021)
Authors: Dahham Alsoud, Bram Verstockt, Claudio Fiocchi, Séverine Vermeire
Pages: S89 - S95Number of pages: 7 - Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease(2021)
Authors: Bram Verstockt, Liesbeth Boets, João Pedro Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1416 - 1418Number of pages: 3 - Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations(2021)
Authors: Nathalie Van den Berghe, Bram Verstockt, Ann Gils, João Pedro Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Paul Declerck, Debby Thomas
Pages: 988 - 993